Deniz Kural, Ph.D. Co-Founder and Chief Executive Officer As CEO, Deniz oversees the deployment of large-scale software systems at Seven Bridges, where he also leads the company's research and development efforts. He was inspired to found Seven Bridges while working for his Ph.D. on the 1,000 Genomes Project, the world's first large-scale genomics project. Deniz identified graph-based data structures as a solution to the growing problem of how to efficiently store and analyze population-scale genomic data. He also spent time working with George Church at Harvard Medical School, where he helped program the Polonator—a next-generation genomic sequencer. As a leader in large-scale analysis of genomic data, Deniz has been an invited speaker at numerous high-profile events, including the influential Cold Spring Harbor Biology of Genomes Conference and the Festival of Genomics in Boston. Deniz earned a B.A. in Mathematics from Harvard College in 2007, and a Ph.D. in genomic structural variation from Boston College. James Sietstra President As President of Seven Bridges, James leads the company's business growth and development. He also serves as a member of the company’s Board of Directors. James has overseen the rapid growth of the company, which now employs more than 230 highly skilled individuals across five offices on three continents. In February 2016 he led the company's $45 million Series A financing with Kryssen Capital, to support continued innovation of the Seven Bridges Platform. James is responsible for setting strategy and oversees the worldwide commercialization of Seven Bridges products. Prior to joining Seven Bridges, James co-founded NutraClick LLC, a technology-enabled, digital marketing company. Together with his partner he profitably grew NutraClick to a $65 million business in its third full year of operation, without raising capital. James earned a B.A. in Government from Harvard College in 2008. Igor Bogicevic Co-Founder and Chief Technology Officer Igor is Chief Technology Officer at Seven Bridges, where he oversees the development and deployment of the robust and scalable computational infrastructure that is necessary for data storage and analysis in the million genome age. He is responsible for building and scaling the Seven Bridges Platform for sophisticated reproducible genomics analysis. Igor is a seasoned software engineer with extensive experience in scalable and distributed architectures and complex partner integrations. As principal engineer at vast.com, he designed and implemented a new data processing and analytics infrastructure built on top of open source solutions, and his system replaced old custom in-house infrastructure, increasing speed by an order of magnitude. He also designed and implemented an initial reporting platform, as well as a data feed and lead API platform used for integration with partners such as AOL, Yahoo, Kelly Blue Book, and Orbitz. Igor previously worked for FNX Solutions (now part of SunGard), and at Bank of America on foreign exchange interfaces and calculations. He was also the Chief System Engineer at EuNET, where he built a new infrastructure for hosting, server colocation, and billing. Brandi Davis-Dusenbery, Ph.D. Senior Vice President of Science & Product Brandi combines her extensive understanding of molecular and cellular biology with the computational expertise required to extract insight from large datasets. In particular, Brandi is passionate about building products that bring together scientists with disparate expertise to scalably and reproducibly learn from biological data. This passion stems from her work as a Postdoctoral Fellow at Harvard University's Department of Stem Cell and Regenerative Biology, where she focused on understanding the transcriptional changes that contribute to motor neuron loss in ALS. Prior to her work with ALS, Brandi identified a novel mechanism of microRNA biogenesis shared by diverse molecular signaling cascades. Brandi's work has been published in Nature, Cell, Molecular Cell and other leading journals. As the scientific lead on the National Cancer Institute's Cancer Genomics Cloud, she has focused on empowering researchers to securely access and analyze petabytes of cancer genomics data. Brandi holds a Ph.D. in Biochemistry from Tufts Sackler School of Medicine and a B.S. in Biochemistry from the University of Rochester. Julia Fan Li, Ph.D. Senior Vice President of Commercial Operations and Head of UK Office Julia leads Seven Bridges’ international expansion efforts from the UK office, including the company’s work with Genomics England building highly accurate variant calling formats using population genome graphs. Prior to joining Seven Bridges, she helped create and manage the pioneering $108 million Global Health Investment Fund, which focuses on accelerating biomedical innovation for diseases that disproportionately impact developing countries. She helped build KPMG's Canadian biotechnology practice before working for Novartis AG and the World Health Organization as a special advisor on R&D financing and coordination. Julia completed her undergraduate double major in finance and immunology from the University of British Columbia and her Ph.D. at the University of Cambridge as a Gates Scholar working on innovative financing for health. She has a life-long love for the life sciences and is passionate about accelerating cancer research and cancer financing at the same time. Bruce Press Senior Vice President of Commercial Operations Heading up the Seven Bridges commercial operations effort with Bill Glauser, Bruce focuses on building relationships with early stage biotechnology companies and all types of pharmaceutical enterprises. He works closely with these organizations to help them leverage the Seven Bridges Platform to streamline analysis of next-generation sequencing data across both clinical and R&D efforts. Prior to his current role, Bruce was director of big data solutions for EMC, where he was responsible for helping clients in the life sciences market build out their big data analytics platforms. He also previously held positions at Alliance Technologies, CallidusCloud and GlaxoSmithKline, where he helped build both on-premises and cloud-based technology platforms, and worked with teams delivering data analytics, data warehousing, clinical informatics and clinical trial and analytic systems. He holds a B.S. in Engineering from The University of Massachusetts and an M.S. in Management from Purdue University. William A. Glauser, Ph.D. Senior Vice President of Commercial Operations Bill is responsible for bringing the Seven Bridges vision for biomedical analysis to the mainstream research market, and focuses on building relationships with clinical organizations, biotechnology companies and academic and hospital labs. He joined Seven Bridges following a 20-year career at Schrödinger, a leader in software and services for life sciences and materials research. As vice president in charge of business development, sales and strategic planning, he helped to catapult the company from a niche player to the dominant provider of molecular modeling solutions. Prior to Schrödinger, he worked in sales at Autodesk, Inc., a leader in 3D design, engineering and entertainment software. Bill holds a Ph.D. in Chemistry from the University of South Florida, and was a Postdoctoral Fellow in Theoretical Chemistry at the University of California, Berkeley. He also earned an M.B.A. at North Carolina State University, where he co-founded a company focused on the production of proteins for use in drug therapies. Bryan C. Spielman Executive Vice President, Strategy and Corporate Development Bryan brings a wealth of knowledge from the healthcare, technology and investment banking sectors, with more than 20 years’ experience developing strategy, leading M&A transactions, and forging partnerships. Prior to joining Seven Bridges, Bryan was Executive Vice President, Strategy and Corporate Development at Medidata Solutions (NASDAQ: MDSO), where he was responsible for defining the company’s corporate strategy and driving impactful relationships with customers, partners and key industry stakeholders. Bryan helped catalyze important new areas of growth for Medidata, such as its focus on deep data and analytics. During his tenure, revenue doubled, the customer base more than tripled and the company's market capitalization increased over 700%. Bryan was previously a founding partner of the Technology Investment Banking Group at Centerview Partners where he focused on deal-making in the fast-moving technology sector. He has held leadership roles in investment banking at UBS Investment Bank and Bear Stearns. Bryan holds an M.B.A. from New York University Stern School of Business and a B.A. from the University of Pennsylvania. He is a member of the Partnership Fund for NYC's Healthcare Advisory Board and actively mentors technology start-ups. Bryan is a frequent speaker at a number of industry and investor conferences, including Fortune Brainstorm TECH, Forbes Healthcare Summit, and Prix Galien MedTech, and has published commentary on how big data transforms healthcare in media such as Forbes, Pharmaceutical Executive, The Hill and Project Syndicate.